Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...

Bristol Myers Squibb (BMY) says its cancer drugs Opdivo and Yervoy improved progression-free survival in a Phase 3 trial for ...

Unusual total active option classes on open include: B2Gold ( BTG ), Verizon ( VZ ), Zscaler ( ZS ), American Express ( AXP ), Mastercard ( MA ), KE Holdings ( BEKE ), Novo Nordisk ( NVO ), Microchip ...

Indian generic drugmaker Dr Reddy's Laboratories reported third-quarter profit below expectations on Thursday, weighed down by pricing pressure in the competitive North American market, their biggest ...

2025 is set to be a game-changing year for cancer research, with cutting-edge therapies and technologies driving unprecedented progress in oncology.

Research analysts at William Blair upped their Q4 2024 earnings estimates for Bristol-Myers Squibb in a report released on Tuesday, January 21st. William Blair analyst M. Phipps now forecasts that the ...

Nuvalent, Inc. shares have fallen approximately 30% after promising updates on its two lead NSCLC candidates rallied the ...

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...

In pancreatic cancer, pelareorep previously demonstrated a strong efficacy signal when administered with gemcitabine, nab-paclitaxel and atezolizumab. Our new safety data indicate its ability to also ...

We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...

Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $57.04 which represents a slight increase of $0.75 or 1.33% from the prior close of $56.29. The stock opened at $56.63 and ...

The aging population and lifestyle-related factors contribute to a surge in pancreatic cancer cases. The aggressive nature of the disease and its high mortality rate demand innovative therapies.